Pharmacoeconomic review report: Tiotropium bromide monohydrate and olodaterol hydrochloride (Inspiolto respimat) for oral inhalation
Inspiolto Respimat (tiotropium bromide monohydrate/olodaterol hydrochloride [TIO/OLO]) is a fixeddose combination of a long‐acting muscarinic antagonist (LAMA), tiotropium, and a long-acting beta2 agonist (LABA), olodaterol, indicated for the long-term, once‐daily maintenance bronchodilator treatmen...
| Corporate Author: | |
|---|---|
| Format: | eBook |
| Language: | English |
| Published: |
Ottawa (ON)
Canadian Agency for Drugs and Technologies in Health
December 2015, 2015
|
| Series: | CADTH common drug review
|
| Subjects: | |
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
| Summary: | Inspiolto Respimat (tiotropium bromide monohydrate/olodaterol hydrochloride [TIO/OLO]) is a fixeddose combination of a long‐acting muscarinic antagonist (LAMA), tiotropium, and a long-acting beta2 agonist (LABA), olodaterol, indicated for the long-term, once‐daily maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. TIO/OLO is available as a multi-use cartridge to be used with the Respimat device, which provides 2.5 mcg of TIO and 2.5 mcg of OLO per actuation. The recommended dose of TIO/OLO is two actuations once daily ( |
|---|---|
| Physical Description: | 1 PDF file (ii, 11 pages) illustrations |